{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T14:04:54Z","timestamp":1784297094223,"version":"3.55.0"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["CIHR, F17-03454"],"award-info":[{"award-number":["CIHR, F17-03454"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000204","name":"Vancouver Foundation","doi-asserted-by":"publisher","award":["UNR18-0005"],"award-info":[{"award-number":["UNR18-0005"]}],"id":[{"id":"10.13039\/501100000204","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000245","name":"Michael Smith Foundation for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000245","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"CIHR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001804","name":"Canada Research Chairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001804","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["P30DA040500"],"award-info":[{"award-number":["P30DA040500"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.cct.2020.105993","type":"journal-article","created":{"date-parts":[[2020,3,16]],"date-time":"2020-03-16T03:12:06Z","timestamp":1584328326000},"page":"105993","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Slow release oral morphine versus methadone for opioid use disorder in the fentanyl era (pRESTO): Protocol for a non-inferiority randomized clinical trial"],"prefix":"10.1016","volume":"91","author":[{"given":"M. Eugenia","family":"Socias","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiru","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupinder","family":"Brar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paxton","family":"Bach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean M.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Fairbairn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cct.2020.105993_bb0005","author":"Ahmad"},{"key":"10.1016\/j.cct.2020.105993_bb0010","author":"Special Advisory Committee on the Epidemic of Opioid Overdoses"},{"issue":"8","key":"10.1016\/j.cct.2020.105993_bb0015","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.2105\/AJPH.2014.301966","article-title":"Determinants of increased opioid-related mortality in the United States and Canada, 1990-2013: a systematic review","volume":"104","author":"King","year":"2014","journal-title":"Am. J. Public Health"},{"issue":"5051","key":"10.1016\/j.cct.2020.105993_bb0020","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.15585\/mmwr.mm655051e1","article-title":"Increases in drug and opioid-involved overdose deaths - United States, 2010-2015","volume":"65","author":"Rudd","year":"2016","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"10.1016\/j.cct.2020.105993_bb0025","series-title":"Illicit Drug Overdose Deaths in BC (January 1 2009\u2013January 31, 2019)","author":"BC Coroners Service","year":"2019"},{"key":"10.1016\/j.cct.2020.105993_bb0030","series-title":"Latest Trends in Opioid-Related Deaths in Ontario: 1991 to 2015","author":"Gomes","year":"2017"},{"issue":"1","key":"10.1016\/j.cct.2020.105993_bb0035","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1360-0443.2010.03140.x","article-title":"Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies","volume":"106","author":"Degenhardt","year":"2011","journal-title":"Addiction"},{"key":"10.1016\/j.cct.2020.105993_bb0040","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.e5945","article-title":"Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis","volume":"345","author":"MacArthur","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.cct.2020.105993_bb0045","doi-asserted-by":"crossref","first-page":"j1550","DOI":"10.1136\/bmj.j1550","article-title":"Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.cct.2020.105993_bb0050","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/HRP.0000000000000075","article-title":"Medication-assisted treatment of opioid use disorder: review of the evidence and future directions","volume":"23","author":"Connery","year":"2015","journal-title":"Harv. Rev. Psychiatr."},{"issue":"6","key":"10.1016\/j.cct.2020.105993_bb0055","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11920-017-0783-9","article-title":"Update on barriers to pharmacotherapy for opioid use disorders","volume":"19","author":"Sharma","year":"2017","journal-title":"Curr. Psychiatr. Rep."},{"key":"10.1016\/j.cct.2020.105993_bb0060","series-title":"A Guideline for the Clinical Management of Opioid Use Disorder","author":"BCCSU","year":"2017"},{"issue":"9","key":"10.1016\/j.cct.2020.105993_bb0065","doi-asserted-by":"crossref","first-page":"E247","DOI":"10.1503\/cmaj.170958","article-title":"Management of opioid use disorders: a national clinical practice guideline","volume":"190","author":"Bruneau","year":"2018","journal-title":"CMAJ"},{"issue":"1","key":"10.1016\/j.cct.2020.105993_bb0070","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/10550887.2016.1100960","article-title":"Retention in medication-assisted treatment for opiate dependence: a systematic review","volume":"35","author":"Timko","year":"2016","journal-title":"J. Addict. Dis."},{"issue":"5","key":"10.1016\/j.cct.2020.105993_bb0075","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1037\/a0037550","article-title":"A naturalistic comparison of the effectiveness of methadone and two sublingual formulations of buprenorphine on maintenance treatment outcomes: findings from a retrospective multisite study","volume":"22","author":"Proctor","year":"2014","journal-title":"Exp. Clin. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.cct.2020.105993_bb0080","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jpain.2014.01.495","article-title":"Methadone overdose and cardiac arrhythmia potential: findings from a review of the evidence for an American Pain Society and College on Problems of Drug Dependence clinical practice guideline","volume":"15","author":"Chou","year":"2014","journal-title":"J. Pain"},{"issue":"5","key":"10.1016\/j.cct.2020.105993_bb0085","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-007629","article-title":"The relative risk of fatal poisoning by methadone or buprenorphine within the wider population of England and Wales","volume":"5","author":"Marteau","year":"2015","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.cct.2020.105993_bb0090","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1521-0391.2009.00005.x","article-title":"Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review","volume":"19","author":"McCance-Katz","year":"2010","journal-title":"Am. J. Addict."},{"issue":"1","key":"10.1016\/j.cct.2020.105993_bb0095","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/jsm.12352","article-title":"The prevalence of sexual dysfunction among male patients on methadone and buprenorphine treatments: a meta-analysis study","volume":"11","author":"Yee","year":"2014","journal-title":"J. Sex. Med."},{"issue":"7","key":"10.1016\/j.cct.2020.105993_bb0100","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/add.14180","article-title":"Extended-release injectable naltrexone for opioid use disorder: a systematic review","volume":"113","author":"Jarvis","year":"2018","journal-title":"Addiction"},{"key":"10.1016\/j.cct.2020.105993_bb0105","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/1472-6963-11-174","article-title":"Client satisfaction among participants in a randomized trial comparing oral methadone and injectable diacetylmorphine for long-term opioid-dependency","volume":"11","author":"Marchand","year":"2011","journal-title":"BMC Health Serv. Res."},{"issue":"3","key":"10.1016\/j.cct.2020.105993_bb0110","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3109\/00952991003736371","article-title":"The role of patient satisfaction in methadone treatment","volume":"36","author":"Kelly","year":"2010","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"10.1016\/j.cct.2020.105993_bb0115","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2147\/PPA.S52060","article-title":"A critical analysis of user satisfaction surveys in addiction services: opioid maintenance treatment as a representative case study","volume":"8","author":"Trujols","year":"2014","journal-title":"Patient Prefer Adherence"},{"issue":"4","key":"10.1016\/j.cct.2020.105993_bb0120","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/add.12440","article-title":"Maintenance treatment for opioid dependence with slow-release oral morphine: a randomized cross-over, non-inferiority study versus methadone","volume":"109","author":"Beck","year":"2014","journal-title":"Addiction"},{"key":"10.1016\/j.cct.2020.105993_bb0125","article-title":"Slow-release oral morphine as maintenance therapy for opioid dependence","volume":"6","author":"Ferri","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"issue":"6","key":"10.1016\/j.cct.2020.105993_bb0130","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1111\/j.1365-2125.2011.03923.x","article-title":"Slow-release oral morphine for opioid maintenance treatment: a systematic review","volume":"71","author":"Jegu","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.cct.2020.105993_bb0135","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-025799","article-title":"Slow release oral morphine versus methadone for the treatment of opioid use disorder","volume":"9","author":"Klimas","year":"2019","journal-title":"BMJ Open"},{"issue":"2","key":"10.1016\/j.cct.2020.105993_bb0140","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/JCP.0000000000000288","article-title":"Self-reported cravings for heroin and cocaine during maintenance treatment with slow-release oral morphine compared with methadone A randomized, crossover clinical trial","volume":"35","author":"Falcato","year":"2015","journal-title":"J. Clin. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.cct.2020.105993_bb0145","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jsat.2014.05.012","article-title":"Safety and tolerability of slow-release oral morphine versus methadone in the treatment of opioid dependence","volume":"47","author":"Hammig","year":"2014","journal-title":"J. Subst. Abus. Treat."},{"issue":"2","key":"10.1016\/j.cct.2020.105993_bb0150","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000368572","article-title":"Mental symptoms and drug use in maintenance treatment with slow-release Oral morphine compared to methadone: results of a randomized crossover study","volume":"21","author":"Verthein","year":"2015","journal-title":"Eur. Addict. Res."},{"issue":"4","key":"10.1016\/j.cct.2020.105993_bb0155","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/j.1465-3362.2011.00353.x","article-title":"After the randomised injectable opiate treatment trial: post-trial investigation of slow-release oral morphine as an alternative opiate maintenance medication","volume":"31","author":"Bond","year":"2012","journal-title":"Drug Alcohol Rev."},{"issue":"2","key":"10.1016\/j.cct.2020.105993_bb0160","doi-asserted-by":"crossref","first-page":"141","DOI":"10.7326\/M17-2373","article-title":"Evaluating slow-release Oral morphine to narrow the treatment gap for opioid use disorders","volume":"168","author":"Socias","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.cct.2020.105993_bb0165","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.e7586","article-title":"SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials","volume":"346","author":"Chan","year":"2013","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.cct.2020.105993_bb0170","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1377\/hlthaff.2012.0846","article-title":"A call for evidence-based medical treatment of opioid dependence in the United States and Canada","volume":"32","author":"Nosyk","year":"2013","journal-title":"Health Aff."},{"key":"10.1016\/j.cct.2020.105993_bb0175","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.drugalcdep.2018.06.020","article-title":"Initial results of a drug checking pilot program to detect fentanyl adulteration in a Canadian setting","volume":"190","author":"Tupper","year":"2018","journal-title":"Drug Alcohol Depend."},{"issue":"4","key":"10.1016\/j.cct.2020.105993_bb0180","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1056\/NEJMoa055255","article-title":"Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence","volume":"355","author":"Fiellin","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"1\u20133","key":"10.1016\/j.cct.2020.105993_bb0185","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.schres.2010.01.021","article-title":"Psychometric evaluation of the Medication Satisfaction Questionnaire (MSQ) to assess satisfaction with antipsychotic medication among schizophrenia patients","volume":"118","author":"Vernon","year":"2010","journal-title":"Schizophr. Res."},{"issue":"3","key":"10.1016\/j.cct.2020.105993_bb0190","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s11136-015-1131-3","article-title":"Evaluating PROMIS(R) instruments and methods for patient-centered outcomes research: patient and provider voices in a substance use treatment setting","volume":"25","author":"Johnston","year":"2016","journal-title":"Qual. Life Res."},{"issue":"3","key":"10.1016\/j.cct.2020.105993_bb0195","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1046\/j.1360-0443.2000.95341912.x","article-title":"Consistency of self-administered and interview-based Addiction Severity Index composite scores","volume":"95","author":"Rosen","year":"2000","journal-title":"Addiction"},{"key":"10.1016\/j.cct.2020.105993_bb0200","series-title":"Proceedings of the 59th Annual Scientific Meeting","article-title":"A comparison of a self-administered ASI with the standard ASI interview, problems of drug dependence, 1997","author":"Cacciola","year":"1998"},{"issue":"1","key":"10.1016\/j.cct.2020.105993_bb0205","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0168-8510(96)00822-6","article-title":"EuroQol: the current state of play","volume":"37","author":"Brooks","year":"1996","journal-title":"Health Policy"},{"issue":"10","key":"10.1016\/j.cct.2020.105993_bb0210","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.jclinepi.2009.12.003","article-title":"The quality of eight health status measures were compared for chronic opioid dependence","volume":"63","author":"Nosyk","year":"2010","journal-title":"J. Clin. Epidemiol."},{"issue":"1","key":"10.1016\/j.cct.2020.105993_bb0215","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1037\/0022-006X.68.1.134","article-title":"The timeline followback reports of psychoactive substance use by drug-abusing patients: psychometric properties","volume":"68","author":"Fals-Stewart","year":"2000","journal-title":"J. Consult. Clin. Psychol."},{"issue":"1","key":"10.1016\/j.cct.2020.105993_bb0220","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1037\/a0030992","article-title":"Reliability of the Timeline Followback for cocaine, cannabis, and cigarette use","volume":"28","author":"Robinson","year":"2014","journal-title":"Psychol. Addict. Behav."},{"key":"10.1016\/j.cct.2020.105993_bb0225","first-page":"CD002207","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"2","author":"Mattick","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"issue":"4","key":"10.1016\/j.cct.2020.105993_bb0230","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1046\/j.1360-0443.2003.00335.x","article-title":"Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients","volume":"98","author":"Mattick","year":"2003","journal-title":"Addiction"},{"issue":"5","key":"10.1016\/j.cct.2020.105993_bb0235","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1017\/S146114570700836X","article-title":"Retention rate and substance use in methadone and buprenorphine maintenance therapy and predictors of outcome: results from a randomized study","volume":"11","author":"Soyka","year":"2008","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.cct.2020.105993_bb0240","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0376-8716(00)00163-0","article-title":"Double-blind randomized trial of buprenorphine and methadone in opiate dependence","volume":"62","author":"Petitjean","year":"2001","journal-title":"Drug Alcohol Depend."},{"issue":"18","key":"10.1016\/j.cct.2020.105993_bb0245","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1056\/NEJM200011023431802","article-title":"A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence","volume":"343","author":"Johnson","year":"2000","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.cct.2020.105993_bb0250","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1176\/appi.ajp.162.2.340","article-title":"Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence","volume":"162","author":"Schottenfeld","year":"2005","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.cct.2020.105993_bb0255","first-page":"CD002209","article-title":"Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence","volume":"3","author":"Mattick","year":"2009","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.cct.2020.105993_bb0260","series-title":"Non-Inferiority Clinical Trials to Establish Effectiveness","author":"Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER)","year":"2016"},{"issue":"24","key":"10.1016\/j.cct.2020.105993_bb0265","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1001\/jama.2012.87802","article-title":"Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement","volume":"308","author":"Piaggio","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.cct.2020.105993_bb0270","series-title":"Adaptive Design Clinical Trials for Drugs and Biologics","author":"Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Guidance for Industry","year":"2010"},{"issue":"24","key":"10.1016\/j.cct.2020.105993_bb0275","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1001\/jama.2012.87802","article-title":"Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement","volume":"308","author":"Piaggio","year":"2012","journal-title":"Jama"},{"key":"10.1016\/j.cct.2020.105993_bb0280","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1471-2288-11-4","article-title":"Assessing methods for dealing with treatment switching in randomised controlled trials: a simulation study","volume":"11","author":"Morden","year":"2011","journal-title":"BMC Med. Res. Methodol."},{"issue":"11","key":"10.1016\/j.cct.2020.105993_bb0285","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/oxfordjournals.aje.a116813","article-title":"Simulation study of confounder-selection strategies","volume":"138","author":"Maldonado","year":"1993","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.cct.2020.105993_bb0290","series-title":"Applied Mixed Models in Medicine","author":"Brown","year":"2006"},{"key":"10.1016\/j.cct.2020.105993_bb0295","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"2","author":"Mattick","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"issue":"4","key":"10.1016\/j.cct.2020.105993_bb0300","article-title":"Assessing methods for dealing with treatment switching in randomised controlled trials: a simulation study","volume":"11","author":"Morden","year":"2011","journal-title":"BMC Med. Res. Methodol."},{"issue":"3","key":"10.1016\/j.cct.2020.105993_bb0305","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1177\/135965350501000310","article-title":"Discordant conclusions from HIV clinical trials--an evaluation of efficacy endpoints","volume":"10","author":"H. A, D. R","year":"2005","journal-title":"Antiviral Ther."},{"issue":"5","key":"10.1016\/j.cct.2020.105993_bb0310","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/j.1741-3737.2011.00861.x","article-title":"Toward best practices in analyzing datasets with missing data: comparisons and recommendations","volume":"73","author":"Johnson","year":"2011","journal-title":"J. Marriage Fam."},{"key":"10.1016\/j.cct.2020.105993_bb0315","series-title":"Economic Evaluation in Clinical Trials","author":"Glick","year":"2014"},{"key":"10.1016\/j.cct.2020.105993_bb0320","series-title":"Cost-Effectiveness in Health and Medicine","author":"Neumann","year":"2017"},{"key":"10.1016\/j.cct.2020.105993_bb0325","series-title":"Drug Abuse Treatment Cost Anslysis Program (DATCAP): User's Manual","author":"French","year":"2003"},{"issue":"5","key":"10.1016\/j.cct.2020.105993_bb0330","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0740-5472(97)00132-3","article-title":"A structured instrument for estimating the economic cost of drug abuse treatment: The Drug Abuse Treatment Cost Analysis Program (DATCAP)","volume":"14","author":"French","year":"1997","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.cct.2020.105993_bb0335","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.drugalcdep.2016.01.021","article-title":"Cost-effectiveness of an internet-delivered treatment for substance abuse: data from a multisite randomized controlled trial","volume":"161","author":"Murphy","year":"2016","journal-title":"Drug Alcohol Depen."},{"issue":"8","key":"10.1016\/j.cct.2020.105993_bb0340","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1111\/add.13807","article-title":"Cost-effectiveness of extended release naltrexone to prevent relapse among criminal-justice-involved persons with a history of opioid use disorder","volume":"112","author":"Murphy","year":"2017","journal-title":"Addiction"},{"issue":"9","key":"10.1016\/j.cct.2020.105993_bb0345","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1111\/j.1360-0443.2010.03001.x","article-title":"Cost-effectiveness of extended buprenorphine\u2013naloxone treatment for opioid-dependent youth: data from a randomized trial","volume":"105","author":"Polsky","year":"2010","journal-title":"Addiction"},{"key":"10.1016\/j.cct.2020.105993_bb0350","doi-asserted-by":"crossref","first-page":"90","DOI":"10.7326\/M18-0227","article-title":"Cost-effectiveness of buprenorphine-naloxone versus extended-release naltrexone to prevent opioid relapse","volume":"170","author":"Murphy","year":"2019","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.cct.2020.105993_bb0355","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugpo.2017.03.008","article-title":"Unintended impacts of regulatory changes to British Columbia Methadone Maintenance Program on addiction and HIV-related outcomes: an interrupted time series analysis","volume":"45","author":"Socias","year":"2017","journal-title":"Int. J. Drug Policy"},{"key":"10.1016\/j.cct.2020.105993_bb0360","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.socscimed.2015.04.008","article-title":"Negotiating structural vulnerability following regulatory changes to a provincial methadone program in Vancouver, Canada: A qualitative study","volume":"133","author":"McNeil","year":"2015","journal-title":"Soc. Sci. Med"},{"key":"10.1016\/j.cct.2020.105993_bb0365","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1747-597X-9-23","article-title":"Differential long-term outcomes for voluntary and involuntary transition from injection to oral opioid maintenance treatment","volume":"9","author":"Oviedo-Joekes","year":"2014","journal-title":"Subst. Abuse Treat Prev. Policy"},{"key":"10.1016\/j.cct.2020.105993_bb0370","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1940-0640-9-21","article-title":"A chance to stop and breathe: participants' experiences in the North American Opiate Medication Initiative clinical trial","volume":"9","author":"Oviedo-Joekes","year":"2014","journal-title":"Addict. Sci. Clin. Pract."},{"key":"10.1016\/j.cct.2020.105993_bb0375","series-title":"BC Centre for Disease Control","author":"BC Overdose Action Exchange II","year":"2017"}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714420300719?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714420300719?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T08:48:36Z","timestamp":1761554916000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551714420300719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":75,"alternative-id":["S1551714420300719"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2020.105993","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Slow release oral morphine versus methadone for opioid use disorder in the fentanyl era (pRESTO): Protocol for a non-inferiority randomized clinical trial","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2020.105993","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105993"}}